Acelyrin, Inc. (NASDAQ:SLRN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Acelyrin, Inc. (NASDAQ:SLRN) have been assigned an average recommendation of “Moderate Buy” from the seven research firms that are covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $23.67.

SLRN has been the topic of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $28.00 price objective on shares of Acelyrin in a research report on Monday, April 1st. Wells Fargo & Company boosted their price target on Acelyrin from $11.00 to $13.00 and gave the company an “equal weight” rating in a report on Thursday, March 21st.

Acelyrin Stock Performance

Shares of Acelyrin stock opened at $5.37 on Friday. The company’s 50 day moving average price is $7.48 and its 200-day moving average price is $7.95. Acelyrin has a 52-week low of $5.34 and a 52-week high of $29.88. The stock has a market capitalization of $528.19 million and a price-to-earnings ratio of -0.51.

Insider Buying and Selling at Acelyrin

In related news, CEO Shao-Lee Lin sold 15,701 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $7.60, for a total value of $119,327.60. Following the sale, the chief executive officer now owns 1,587,335 shares in the company, valued at approximately $12,063,746. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Institutional Trading of Acelyrin

Institutional investors have recently bought and sold shares of the company. venBio Partners LLC bought a new position in shares of Acelyrin in the second quarter worth approximately $80,616,000. Vanguard Group Inc. lifted its position in Acelyrin by 93.0% in the 4th quarter. Vanguard Group Inc. now owns 6,155,910 shares of the company’s stock valued at $45,923,000 after acquiring an additional 2,966,883 shares in the last quarter. Blue Owl Capital Holdings LP purchased a new stake in Acelyrin during the 4th quarter valued at $17,106,000. FMR LLC increased its holdings in shares of Acelyrin by 20.2% in the 3rd quarter. FMR LLC now owns 8,961,726 shares of the company’s stock worth $89,914,000 after purchasing an additional 1,505,488 shares in the last quarter. Finally, Decheng Capital LLC purchased a new position in shares of Acelyrin in the fourth quarter worth $10,227,000. 87.31% of the stock is owned by hedge funds and other institutional investors.

About Acelyrin

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.